-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%
Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) fell 5.3% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21. 6,148 shares were traded during trading, a decline of 82% from the average session volume of 33,482 shares. The stock had previously closed at $3.39.
Wall Street Analyst Weigh In
Separately, Credit Suisse Group lowered their price objective on shares of Candel Therapeutics to $11.00 in a research report on Monday, August 15th.
Get Candel Therapeutics alerts:Candel Therapeutics Stock Down 5.3 %
The company has a debt-to-equity ratio of 0.34, a quick ratio of 14.86 and a current ratio of 14.86. The stock has a market capitalization of $92.74 million, a P/E ratio of -3.96 and a beta of 0.95. The stock's fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $3.81.
Institutional Investors Weigh In On Candel Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Empirical Asset Management LLC bought a new stake in shares of Candel Therapeutics in the 1st quarter valued at $61,000. Kestra Advisory Services LLC bought a new stake in shares of Candel Therapeutics in the 1st quarter valued at $64,000. 683 Capital Management LLC bought a new stake in shares of Candel Therapeutics in the 4th quarter valued at $320,000. BlackRock Inc. boosted its stake in shares of Candel Therapeutics by 15.5% in the 1st quarter. BlackRock Inc. now owns 132,322 shares of the company's stock valued at $674,000 after purchasing an additional 17,708 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Candel Therapeutics in the 2nd quarter valued at $2,408,000. 21.97% of the stock is owned by institutional investors.Candel Therapeutics Company Profile
(Get Rating)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Featured Articles
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) fell 5.3% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21. 6,148 shares were traded during trading, a decline of 82% from the average session volume of 33,482 shares. The stock had previously closed at $3.39.
坎德爾治療公司(納斯達克代碼:CADL-GET評級)的股價在週三午盤交易中下跌5.3%。該公司股價低至3.20美元,最新報3.21美元。當日成交量為6,148股,較33,482股的平均日成交量下降82%。該股此前收盤價為3.39美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, Credit Suisse Group lowered their price objective on shares of Candel Therapeutics to $11.00 in a research report on Monday, August 15th.
另外,瑞士信貸集團在8月15日星期一的一份研究報告中將Candel治療公司的股票目標價下調至11.00美元。
Candel Therapeutics Stock Down 5.3 %
Candel治療公司股價下跌5.3%
The company has a debt-to-equity ratio of 0.34, a quick ratio of 14.86 and a current ratio of 14.86. The stock has a market capitalization of $92.74 million, a P/E ratio of -3.96 and a beta of 0.95. The stock's fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $3.81.
該公司的負債權益比率為0.34,速動比率為14.86,流動比率為14.86。該股市值為9,274萬美元,市盈率為-3.96,貝塔係數為0.95。該股的50日簡單移動均線為3.41美元,200日簡單移動均線為3.81美元。
Institutional Investors Weigh In On Candel Therapeutics
機構投資者看好Candel治療公司
Candel Therapeutics Company Profile
坎德爾治療公司簡介
(Get Rating)
(獲取評級)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Candel Treateutics,Inc.是一家臨牀階段的生物製藥公司,致力於為癌症患者開發免疫療法。該公司開發了CAN-2409,這是治療胰腺癌的第二階段臨牀試驗;治療前列腺癌的第三階段臨牀試驗;以及治療肺癌的第二階段臨牀試驗,以及治療高級別膠質瘤的Ib/II階段臨牀試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 免費獲取StockNews.com關於Candel治療(CADL)的研究報告
- 對塔吉特來説,最糟糕的時期可能已經過去,但這隻股票買起來安全嗎?
- 這些液態天然氣股票準備好上行了嗎?
- 內部人士正在買入的兩隻有趣的股票
- 諾華在避險市場中仍是一隻冒險的股票
- 連續60年提高股息的3只防御性股票
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《秋茄治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Candel Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧